

<b>HEALTH PLAN POLICY</b>	
<b>Policy Title:</b> Hematopoietic Stem Cell Transplantation (HSCT) – Aplastic Anemia, Sickle Cell Disease and Thalassemia	<b>Policy Number:</b> MUM43 <b>Revision:</b> B
<b>Department:</b> Medical Management	<b>Sub-Department:</b> Utilization Management
<b>Applies to Product Lines:</b> <input type="checkbox"/> Medicaid <span style="float: right;"><input checked="" type="checkbox"/> USFHP</span> <input type="checkbox"/> Children’s Health Insurance Plan <span style="float: right;"><input checked="" type="checkbox"/> Commercial Insured</span> <input checked="" type="checkbox"/> Health Insurance Exchange <span style="float: right;"><input type="checkbox"/> Non Insured Business</span> <input checked="" type="checkbox"/> Medicare	
<b>Origination/Effective Date:</b> 03/08/2018	
<b>Reviewed Date(s):</b>	<b>Revision Date(s):</b> 04/24/2019, 05/18/2020

**SCOPE:**

The purpose of this policy is to define the process utilized for medical necessity review for use of hematopoietic stem cell transplantation (HSCT) in the treatment of aplastic anemia, sickle cell disease, and Thalassemia Major.

**DEFINITIONS AND ACRONYMS:**

- **Hematopoietic Stem Cell Transplantation (HSCT)**
- **Multisystem Organ Failure (MSOF)** - of heart, lungs and/or kidneys

**POLICY:**

HSCT is considered under selective circumstances to be useful in a variety of bone marrow conditions in relation to red blood cell production. Acquired aplastic anemia (without red cell production) caused by drugs, infection, immune deficits and various toxins, is considered a candidate for HSCT. Anemias of qualitatively flawed red cell production such as sickle cell disease and/or thalassemia major are two other common conditions for HSCT.

A host of genetic conditions ranging from immune deficiencies to storage related diseases as well as leukodystrophies are also HSCT possibilities.

**Medical Necessity is Established for the Following 3 Conditions**

- A. Aplastic Anemia
  - 55 years old or younger; if older than 55, then must have previously been treated with immunosuppressive therapy
- B. Sickle Cell Disease
  - Less than 16 years old with homozygous sickle cell disease with MSOF complications
- C. Thalassemia Major
  - 30 years old or less with no liver disease

**HEALTH PLAN POLICY**

**Policy Title:** Hematopoietic Stem Cell Transplantation (HSCT) – Aplastic Anemia, Sickle Cell Disease and Thalassemia

**Policy Number:** MUM43  
**Revision:** B

**REFERENCES:**


- Bone Marrow Transplant 2008; 41:109-117
- Hematology Oncology Stem Cell Therapy 2017

**RELATED DOCUMENTS:**

None



Nancy Horstmann  
Chief Executive Officer Health Plans



David Engleking, M.D.  
Medical Director

**REVISION HISTORY:**

<b>Revision</b>	<b>Date</b>	<b>Description of Change</b>	<b>Committee</b>
New	03/08/2018	Initial release.	Executive Leadership
A	04/24/2019	Annual review. Product lines updated.	Executive Leadership
B	05/18/2020	Annual review. No change to policy content.	Executive Leadership